Marco Tuccori

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 22

Top Topics

Coronavirus Disease

Monoclonal Antibody

Systematic Review

Rheumatoid Arthritis Patients

Top Venues

Expert opinion on drug discovery

Pharmaceuticals (Basel, Switzerland)

International journal of environmental research and public health

This page only lists publications with an associated author ORCID identifier.

Publications

Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Marco Tuccori
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence. Expert opinion on drug discovery 18 (3) (2023)
Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Marco Tuccori
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence. Expert opinion on drug discovery 18 (3) (2023)
Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Marco Tuccori
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence. Expert opinion on drug discovery 18 (3) (2023)
Irma Convertino, Valentina Lorenzoni, Rosa Gini, Giuseppe Turchetti, Elisabetta Fini, Sabrina Giometto, Claudia Bartolini, Olga Paoletti, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Corrado Blandizzi, Marco Tuccori, Ersilia Lucenteforte
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis. Pharmaceuticals (Basel, Switzerland) 16 (3) (2023)
Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Marco Tuccori
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence. Expert opinion on drug discovery (2023)
Irma Convertino, Valentina Lorenzoni, Rosa Gini, Giuseppe Turchetti, Elisabetta Fini, Sabrina Giometto, Claudia Bartolini, Olga Paoletti, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Corrado Blandizzi, Marco Tuccori, Ersilia Lucenteforte
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis. Pharmaceuticals (Basel, Switzerland) 16 (3) (2023)
Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Sara Ferraro, Irma Convertino, Marco Tuccori
Comment on: "Deliberate Self-Poisoning: Real-Time Characterisation of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System". Drug safety (2023)
Giuseppe Roberto, Olga Paoletti, Sara Ferraro, Giulia Hyeraci, Massimo Franchini, Rosa Gini, Daniele Focosi, Marco Tuccori
Cases of acquired hemophilia A following COVID-19 vaccines: cogent safety signal or possible reporting/detection bias? Preliminary evidence from Tuscany, Italy. Pharmacoepidemiology and drug safety (2023)
Sara Ferraro, Irma Convertino, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Marco Tuccori
Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option. Expert opinion on drug discovery (2023)
Salvatore Crisafulli, Zakir Khan, Yusuf Karatas, Marco Tuccori, Gianluca Trifirò
An overview of methodological flaws of real-world studies investigating drug safety in the post-marketing setting. Expert opinion on drug safety (2023)
Irma Convertino, Valentina Lorenzoni, Rosa Gini, Giuseppe Turchetti, Elisabetta Fini, Sabrina Giometto, Claudia Bartolini, Olga Paoletti, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Corrado Blandizzi, Marco Tuccori, Ersilia Lucenteforte
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis. Pharmaceuticals (Basel, Switzerland) 16 (3) (2023)
Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Marco Tuccori
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence. Expert opinion on drug discovery (2023)
Marco Tuccori, Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Giulia de Luca, Massimo Franchini, Daniele Focosi
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall. Expert opinion on drug discovery 17 (6) (2022)
Daniele Focosi, Massimo Franchini, Marco Tuccori, Mario Cruciani
Efficacy of High-Dose Polyclonal Intravenous Immunoglobulin in COVID-19: A Systematic Review. Vaccines 10 (1) (2022)
Sabrina Giometto, Silvia Tillati, Laura Baglietto, Nicola de Bortoli, Marta Mosca, Marco Conte, Marco Tuccori, Rosa Gini, Ersilia Lucenteforte
Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks. International journal of environmental research and public health 19 (11) (2022)
Daniele Focosi, Marco Tuccori
Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy. Pathogens (Basel, Switzerland) 11 (8) (2022)
Daniele Focosi, Marco Tuccori, Massimo Franchini
The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19. Life (Basel, Switzerland) 11 (2) (2021)
Daniele Focosi, Marco Tuccori, Andreina Baj, Fabrizio Maggi
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. Viruses 13 (7) (2021)
Irma Convertino, Sabrina Giometto, Rosa Gini, Massimiliano Cazzato, Marco Fornili, Giulia Valdiserra, Emiliano Cappello, Sara Ferraro, Claudia Bartolini, Olga Paoletti, Silvia Tillati, Laura Baglietto, Giuseppe Turchetti, Leopoldo Trieste, Valentina Lorenzoni, Corrado Blandizzi, Marta Mosca, Marco Tuccori, Ersilia Lucenteforte
Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study. Journal of clinical medicine 10 (24) (2021)
Marco Tuccori, Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Daniele Focosi, Corrado Blandizzi
The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance. Drug safety 43 (8) (2020)
Sara Ferraro, Marco Tuccori, Irma Convertino, Giulia Valdiserra, Emiliano Cappello, Fabrizio Maggi, Corrado Blandizzi, Daniele Focosi
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs. British journal of clinical pharmacology 87 (5) (2020)
Irma Convertino, Marco Tuccori, Sara Ferraro, Giulia Valdiserra, Emiliano Cappello, Daniele Focosi, Corrado Blandizzi
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Critical care (London, England) 24 (1) (2020)